Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid - PubMed (original) (raw)

Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid

H Hatakeyama et al. Gene Ther. 2007 Jan.

Abstract

For successful cancer gene therapy via intravenous (i.v.) administration, it is essential to optimize the stability of carriers in the systemic circulation and the cellular association after the accumulation of the carrier in tumor tissue. However, a dilemma exists regarding the use of poly(ethylene glycol) (PEG), which is useful for conferring stability in the systemic circulation, but is undesirable for the cellular uptake and the following processes. We report the development of a PEG-peptide-lipid ternary conjugate (PEG-Peptide-DOPE conjugate (PPD)). In this strategy, the PEG is removed from the carriers via cleavage by a matrix metalloproteinase (MMP), which is specifically expressed in tumor tissues. An in vitro study revealed that the PPD-modified gene carrier (Multifunctional Envelope-type Nano Device: MEND) exhibited pDNA expression activity that was dependent on the MMP expression level in the host cells. In vivo studies further revealed that the PPD was potent in stabilizing MEND in the systemic circulation and facilitating tumor accumulation. Moreover, the i.v. administration of PPD or PEG/PPD dually-modified MEND resulted in the stimulation of pDNA expression in tumor tissue, as compared with a conventional PEG-modified MEND. Thus, MEND modified with PPD is a promising device, which has the potential to make in vivo cancer gene therapy achievable.

PubMed Disclaimer

Similar articles

• Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.
  Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H. Hatakeyama H, et al. Biomaterials. 2011 Jun;32(18):4306-16. doi: 10.1016/j.biomaterials.2011.02.045. Epub 2011 Mar 22. Biomaterials. 2011. PMID: 21429576
• [Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid].
  Hatakeyama H, Akita H, Kogure K, Harashima H. Hatakeyama H, et al. Yakugaku Zasshi. 2007 Oct;127(10):1549-56. doi: 10.1248/yakushi.127.1549. Yakugaku Zasshi. 2007. PMID: 17917417 Review. Japanese.
• A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
  Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. Hatakeyama H, et al. J Control Release. 2009 Oct 15;139(2):127-32. doi: 10.1016/j.jconrel.2009.06.008. Epub 2009 Jun 21. J Control Release. 2009. PMID: 19540888
• A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene.
  Yu W, Pirollo KF, Rait A, Yu B, Xiang LM, Huang WQ, Zhou Q, Ertem G, Chang EH. Yu W, et al. Gene Ther. 2004 Oct;11(19):1434-40. doi: 10.1038/sj.gt.3302304. Gene Ther. 2004. PMID: 15229629
• A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.
  Hatakeyama H, Akita H, Harashima H. Hatakeyama H, et al. Adv Drug Deliv Rev. 2011 Mar 18;63(3):152-60. doi: 10.1016/j.addr.2010.09.001. Epub 2010 Sep 15. Adv Drug Deliv Rev. 2011. PMID: 20840859 Review.

Cited by

• Matrix metalloproteinase responsive hydrogel microplates for programmed killing of invasive tumour cells.
  Cook AB, Palange A, Schlich M, Bellotti E, Brahmachari S, di Francesco M, Decuzzi P. Cook AB, et al. RSC Appl Polym. 2023 Aug 14;1(1):19-29. doi: 10.1039/d3lp00057e. eCollection 2023 Sep 25. RSC Appl Polym. 2023. PMID: 38013908 Free PMC article.
• Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.
  Yihunie W, Nibret G, Aschale Y. Yihunie W, et al. Clin Pharmacol. 2023 Aug 3;15:77-98. doi: 10.2147/CPAA.S418314. eCollection 2023. Clin Pharmacol. 2023. PMID: 37554660 Free PMC article. Review.
• Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood-Brain Barrier (BBB).
  Ghorai SM, Deep A, Magoo D, Gupta C, Gupta N. Ghorai SM, et al. Pharmaceutics. 2023 Jul 21;15(7):1999. doi: 10.3390/pharmaceutics15071999. Pharmaceutics. 2023. PMID: 37514185 Free PMC article. Review.
• Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.
  Lee J, Choi MK, Song IS. Lee J, et al. Pharmaceuticals (Basel). 2023 May 29;16(6):802. doi: 10.3390/ph16060802. Pharmaceuticals (Basel). 2023. PMID: 37375753 Free PMC article. Review.
• A Winning New Combination? Toward Clinical Application in Oncology.
  Maqsood Q, Sumrin A, Iqbal M, Hussain N, Mahnoor M, Zafar Saleem M, Perveen R. Maqsood Q, et al. Cancer Control. 2023 Jan-Dec;30:10732748231175240. doi: 10.1177/10732748231175240. Cancer Control. 2023. PMID: 37166227 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information